COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02033239
Recruitment Status : Completed
First Posted : January 10, 2014
Last Update Posted : January 18, 2017
Information provided by (Responsible Party):
Novo Nordisk A/S

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : June 2014
Actual Study Completion Date : June 2014
Heise T, Pieber TR, Danne T, Erichsen L, Haahr H. Faster Onset and Greater Early Exposure and Glucose-Lowering Effect with Faster-Acting Insulin Aspart vs. Insulin Aspart: A Pooled Analysis in Subjects with Type 1 Diabetes. Diabetes. 2016; Suppl. 1: A239. doi:10.2337/db16-861-1374

Publications automatically indexed to this study by Identifier (NCT Number):